Ligand Q4 revenue up 52% to $42.8M; core adj EPS $1.27; reaffirms 2025 guidance

LIGAND PHARMACEUTICALS INC

2024-FY EPS reported -$0.22 revenue$167,133,000

Q4 total rev $42.8M (+52% YoY); royalties $34.8M (+55%) driven by Qarziba and Filspari.
Core adjusted net income from cont ops $25.2M ($1.27/diluted) vs $18.6M ($1.05) prior year.
Full year adj net income $156.0M ($8.25/diluted); core adj $108.5M ($5.74/diluted).
Reaffirms 2025 guidance: total rev $180-200M, adjusted EPS $6.00-$6.25.
Closed $50M royalty investment in Castle Creek Biosciences for D-Fi Phase 3 study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.